Metabolic & Weight
Retatrutide
An investigational "triple agonist" targeting three metabolic receptors at once, generating significant interest for weight and metabolic research.
What it is
Retatrutide is one of the newest and most talked-about metabolic peptides. It's a triple agonist, meaning it activates three different receptors — GIP, GLP-1 and glucagon — that together govern appetite, blood sugar and energy use.
How it's thought to work
GLP-1 and GIP signalling reduce appetite and improve glucose handling, while adding glucagon activity is thought to increase energy expenditure. Hitting all three may produce a larger metabolic effect than single- or dual-agonists.
Potential health benefits
Studied for:
- Substantial weight reduction in early trials.
- Improved glucose control.
- Potentially higher energy expenditure via the glucagon arm.
What the research says
Early-phase human trials of retatrutide have reported some of the largest weight reductions seen for this drug class. It remains investigational — still moving through the clinical pipeline — so long-term safety is not yet established.
Considerations
A research compound only. Metabolic agonists affect appetite, digestion and blood sugar — qualified medical supervision is strongly advised.
Recommended suppliers
Where to find research-grade Retatrutide
If you're sourcing Retatrutide for research, we recommend Pharma Tides— independently tested, >99% HPLC purity, with a Certificate of Analysis on every batch.
View Retatrutide at Pharma Tides